Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 1;13(3):842.
doi: 10.3390/jcm13030842.

Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy

Fraser C Goldie  1 , Matthew M Y Lee  1 , Caroline J Coats  1   2 , Sabrina Nordin  1   2
Affiliations
Review

Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy

Fraser C Goldie et al. J Clin Med. .

Abstract

Hypertrophic cardiomyopathy (HCM) is characterized by abnormal growth of the myocardium with myofilament disarray and myocardial hyper-contractility, leading to left ventricular hypertrophy and fibrosis. Where culprit genes are identified, they typically relate to cardiomyocyte sarcomere structure and function. Multi-modality imaging plays a crucial role in the diagnosis, monitoring, and risk stratification of HCM, as well as in screening those at risk. Following the recent publication of the first European Society of Cardiology (ESC) cardiomyopathy guidelines, we build on previous reviews and explore the roles of electrocardiography, echocardiography, cardiac magnetic resonance (CMR), cardiac computed tomography (CT), and nuclear imaging. We examine each modality's strengths along with their limitations in turn, and discuss how they can be used in isolation, or in combination, to facilitate a personalized approach to patient care, as well as providing key information and robust safety and efficacy evidence within new areas of research.

Keywords: cardiac computed tomography; cardiac magnetic resonance imaging; echocardiography; hypertrophic cardiomyopathy; multi-modality imaging; nuclear imaging.

PubMed Disclaimer

Conflict of interest statement

F.C.G. has no conflicts of interest to declare; M.M.Y.L. has received research grants through his institution, the University of Glasgow, from AstraZeneca and Boehringer Ingelheim and Roche Diagnostics, and is a member of a Trial Steering Committee for Cytokinetics and a Clinical Endpoints Committee for Bayer; C.J.C. is a member of a Steering Committee and has received advisory fees for Cytokinetics and speaker fees for Alnylam and Roche; S.N. has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Cardiac sarcomere components and corresponding genes, and main imaging modalities with examples of their utility. ACTC1: α actin, CRISP3: Cysteine−rich secretory protein 3, HCM: Hypertrophic cardiomyopathy, MYBPC3: Cardiac myosin−binding protein C3, MYH7: Myosin heavy chain 7, MYL2: Myosin light chain−2, MYL3: Myosin light chain3, MYZO2: Myozenin 2 (calsarcin 1), TNNC1: Troponin C1, TNNI3: Troponin I3, TNNT2: Troponin T2, TPM1: Tropomyosin 1.
Figure 2
Figure 2
Patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy with cardiovascular magnetic resonance. (A) Neutral pattern; (B) reverse curve hypertrophy pattern; (C) apical hypertrophy pattern; (D) 4-chamber view of basal septal hypertrophy pattern; (E) 3-chamber view of basal septal hypertrophy pattern.
Figure 3
Figure 3
Left ventricular outflow tract obstruction (LVOT) in hypertrophic cardiomyopathy with transthoracic echocardiogram. (A,B) Systolic anterior movement of anterior mitral valve leaflet on parasternal long axis and M-mode. (C) Colour flow showing LVOT acceleration with associated posteriorly directed mitral regurgitation. (D) Continuous wave Doppler showing typical ‘dagger shape’ Doppler tracing indicating LVOT obstruction.
Figure 4
Figure 4
Hypertrophic cardiomyopathy and HCM phenocopies with tissue characterization assessment using CMR. In HCM, native T1 and ECV can be either normal or mildly elevated with patchy midwall LGE especially seen in hypertrophic regions. LGE at RV insertion points can also be present. In cardiac amyloidosis, native T1 and ECV is significantly elevated with either subendocardial or transmural LGE throughout the myocardium. In Fabry disease, native T1 is typically low with elevated T2 at corresponding LGE areas with typical basal inferolateral LGE.
See this image and copyright information in PMC

References

    1. Seidman C.E., Seidman J.G. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history. Circ. Res. 2011;108:743–750. doi: 10.1161/CIRCRESAHA.110.223834. - DOI - PMC - PubMed
    1. Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R., Basso C., Bezzina C.R., Biagini E., Blom N.A., de Boer R.A., et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) Eur. Heart J. 2023;44:3503–3626. doi: 10.1093/eurheartj/ehad194. - DOI - PubMed
    1. Maron M.S., Link M.S., Udelson J.E., Kuvin J.T., Pandian N.G., Olivotto I., Nistri S., Cecchi F., Maron B.J., Zenovich A.G., et al. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Circulation. 2006;114:2232–2239. doi: 10.1161/CIRCULATIONAHA.106.644682. - DOI - PubMed
    1. Spudich J.A. The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy. Biochem. Soc. Trans. 2015;43:64–72. doi: 10.1042/BST20140324. - DOI - PMC - PubMed
    1. Cheng Z., Fang T., Huang J., Guo Y., Alam M., Qian H. Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment. Front. Cardiovasc. Med. 2021;8:722340. doi: 10.3389/fcvm.2021.722340. - DOI - PMC - PubMed

LinkOut - more resources